| abstract |
SUMMARY OF THE INVENTION The present invention relates to a group of formula I wherein X is a 5-6 membered monocyclic or 9-12 membered fused bicyclic, unsubstituted or substituted ring having at least one heteroatom selected from the group consisting of nitrogen, oxygen and sulfur; Z is hydrogen, 5-6 membered monocyclic or 9-12 membered condensed bicyclic, substituted or unsubstituted, having at least one heteroatom in the ring, which may be nitrogen, oxygen or sulfur; Ar is an optionally substituted aromatic or heteroaromatic ring; L1, L2 and L3 are each independently a bond, -CO, -SO2 or -CH2, wherein at least one of L2 and L3 must be -CO or -SO2, and wherein L1 can also be a C2-C5 alkylene group it may be replaced by a nitrogen atom and wherein the alkylene group itself may be optionally substituted with a C 3 -C 4 bridging alkylene group; and L2 and L3 are independently selected from the group consisting of -SO2NH, -CONH, -SO2NHCH2, and -CONHCH2; n is 0, 1 or 2; R1 and R2 are independently hydrogen; linear, branched or cyclic C 1 -C 6 optionally substituted alkyl, and wherein R 2 may be Y-linked alkylene; and Y contains at least one aromatic, heteroaromatic, or other heterocyclic, substituted or unsubstituted ring moiety that is directly linked to L3, a compound, salt or prodrug thereof, which can be used to influence chemokine receptors and thereby treat chemokine receptor mediated conditions. HE |